Skip to search formSkip to main contentSkip to account menu

S-CKD602

A sterically stabilized, pegylated liposomal formulation containing CKD602, a semi-synthetic analogue of campthotecin with potential antitumor… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pegylated Liposomal Belotecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.
2545 Background: CKD-602, a semi-synthetic analogue of campothecin, is a potent topoisomerase I inhibitor. S-CKD602, a PEGylated… 
2014
2014
Immune mechanisms regulating pharmacokinetics and pharmacodynamics of PEGylated liposomal anticancer agents
2012
2012
Abstract 754: The effect of CC chemokine ligand-2 (CCL2/MCP-1) and CC chemokine ligand-5 (CCL5/RANTES) on the pharmacokinetics (PK) and the pharmacodynamics (PD) of pegylated liposomal CKD602 (S…
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Introduction: S-CKD602, pegylated liposomal… 
2011
2011
Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models
Liposomes, such as pegylated-liposomal CKD-602 (S-CKD602), undergo catabolism by macrophages and dendritic cells (DCs) of the… 
2011
2011
Abstract 1295: Relationship between pharmacokinetic (PK) sampling schema and reported PK variability of liposomes in patients
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: Liposomal formulations offer advantages… 
2010
2010
Abstract 3700: Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and optisomal topotecan (TLI) in rats
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Introduction: S-CKD602 is a pegylated liposomal… 
2009
2009
CKD-602 in Patients with Advanced Malignancies Phase I and Pharmacokinetic Study of Pegylated Liposomal
Purpose: S-CKD602 is a pegylated liposomal formulation of CKD602, a semisynthetic camptothecin analogue. Pegylated (STEALTH… 
2006
2006
Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.
2013 Background: S-CKD602 is a pegylated STEALTH liposomal formulation of CKD-602, a semi-synthetic analogue of camptothecin (CPT… 
2006
2006
Plasma, tissue and tumor disposition of STEALTH® liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts
3064 Introduction: S-CKD602 is a STEALTH® liposomal formulation of CKD-602, a camptothecin (CPT) analogue. The cytotoxicity of… 
2005
2005
Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors
2069 Background: S-CKD602 is a pegylated STEALTH liposomal formulation of CKD-602, a semi-synthetic analogue of camptothecin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)